James Boylan, Enavate Sciences CEO

James Boy­lan snags $300M to hunt for biotech deals af­ter leav­ing SVB

Af­ter three decades in health­care in­vest­ment bank­ing, cul­mi­nat­ing in serv­ing as SVB pres­i­dent, James Boy­lan is head­ed to the oth­er side of the in­dus­try.

Specif­i­cal­ly, he’s the new CEO of Pa­tient Square Cap­i­tal’s biotech in­vest­ment com­pa­ny Ena­vate Sci­ences, which launch­es Mon­day with $300 mil­lion to go af­ter “mid­dle in­nings” pri­vate and pub­lic biotechs.

“The op­por­tu­ni­ty to re­al­ly sit shoul­der to shoul­der with peo­ple that used to be my clients and now will be my part­ners was so ex­cit­ing it pulled me out of re­tire­ment,” Boy­lan told End­points News af­ter tak­ing a year off to be with fam­i­ly.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.